Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 32 (22) 2311-2317
Year:
2014
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
3
Parents:
944  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U10 CA047577, U10 CA032291, CA33601, P30 CA016672, U10 CA077658, CA47577, CA32291, N01 CA032102, U10 CA021115, U10 CA031946, CA3360, CA77651, U10 CA033601, U10 CA180821, U10 CA045418, U10 CA032102, U10 CA047559, U10 CA077651, P30 CA015083, U10 CA180882, CA47559, CA45418, U10 CA180820, CA25224, CA77658, U10 CA180867, U10 CA180838, CA21115, U10 CA025224, U10 CA180888, CA31946  
Corr. Author:
 
Authors:
                               
Networks:
 
Study
CALGB-40101
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Bc5, ORIGINAL REPORTS, Breast Cancer